Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the ...

If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.

Eli Lilly (NYSE:LLY) has entered a collaboration and licensing agreement with AlzeCure Pharma for global rights to Alzstatin ACD680, a preclinical Alzheimer's therapy. The deal structure includes ...

STOCKHOLM, SE / ACCESS Newswire / June 9, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's ...